Phase II Trial to Validate Markers for a Response Evaluation of a Combined Therapy in Patients With HER2+ Breast Cancer
Condition(s):Carcinoma, Ductal, BreastLast Updated:September 17, 2019Terminated
Hide Studies Not Open or Pending
Condition(s):Carcinoma, Ductal, BreastLast Updated:September 17, 2019Terminated
Condition(s):Newly Diagnosed Operative Invasive Ductal Breast Carcinoma Stage I-IILast Updated:July 22, 2015Terminated
Condition(s):Carcinoma, Ductal, BreastLast Updated:March 22, 2023Active, not recruiting
Condition(s):Breast Ductal Carcinoma in SituLast Updated:August 6, 2019Recruiting
Condition(s):Mammary Ductal CarcinomaLast Updated:December 2, 2011Unknown status
Condition(s):Ductal Breast Carcinoma In SituLast Updated:June 22, 2023Active, not recruiting
Condition(s):Female Breast Neoplasms; Carcinoma, Ductal, BreastLast Updated:January 12, 2012Completed
Condition(s):Carcinoma, Ductal, Breast; MenopausalLast Updated:October 22, 2020Completed
Condition(s):Invasive Ductal Breast CarcinomaLast Updated:September 27, 2022Completed
Condition(s):Invasive Ductal Breast CarcinomaLast Updated:March 6, 2024Completed
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.